Influx Healthtech Limited, a Mumbai-based healthcare contract manufacturing company, is launching its Initial Public Offering (IPO) on June 18, 2025, aiming to raise ₹58.57 crore. The company, which started operations in 2020, functions as a Contract Development and Manufacturing Organisation (CDMO) offering end-to-end product development and manufacturing services across nutraceuticals, cosmetics, ayurvedic, homecare, and pharmaceuticals.

IPO Details and Timeline

The Influx Healthtech IPO is a Book Built Issue worth ₹58.57 crore, consisting of:

• A fresh issue of 50.00 lakh equity shares amounting to ₹48.00 crore

• An Offer for Sale (OFS) of 11.00 lakh equity shares totalling ₹10.57 crore

IPO Subscription Window:

• Opens: June 18, 2025

• Closes: June 20, 2025

Allotment Finalisation Date: June 23, 2025
Tentative Listing Date: June 25, 2025
Listing Platform: NSE SME

The IPO price band is fixed between ₹91 and ₹96 per equity share. At the upper end of the price band, the market capitalisation is estimated at ₹222.24 crore.

Investment and Lot Size

The lot size for the IPO is 1,200 shares:

• Retail Investors must invest a minimum of ₹1,15,200

• High-Net-Worth Individuals (HNIs) need to apply for a minimum of 2 lots (2,400 shares) at ₹2,30,400

The book running lead manager for the issue is Rarever Financial Advisors Private Limited, and Maashitla Securities Private Limited is the registrar. R.K. Stockholding Private Limited will act as the market maker.

Company Overview

Founded in 2020, Influx Healthtech Limited has quickly become a trusted name in healthcare manufacturing. It provides customised, scalable, and quality-driven production solutions to a broad client base. The company caters to diverse segments including Nutraceuticals, Ayurvedic formulations, Homecare products, and Cosmetics.

Promoter Background:

• Mr. Munir Abdul Ganee Chandniwala: ~22 years of experience across healthcare verticals

• Mrs. Shirin Munir Ahmed Chandniwala: ~12 years in packaging material trading

• Mr. Abdul Ganee Abdul Rasul Chandniwala: ~21 years in pharmaceutical manufacturing

Financial Performance

Influx Healthtech has demonstrated steady growth across revenues, profits, and margins.

This consistent increase in profitability and margins is a positive indicator of the company’s operational efficiency and scalability.

Valuation and Key Ratios

• Pre-Issue EPS (FY24): ₹7.36

• Post-Issue EPS: ₹5.77

• Pre-Issue P/E Ratio: 13.04x

• Post-Issue P/E Ratio: 16.63x

• Industry Average P/E: 29x

Other Key Metrics:

• Return on Capital Employed (ROCE): 49.17%

• Return on Equity (ROE): 36.98%

• Return on Net Worth (RoNW): 36.98%

Disclaimer

This article is for educational and informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and consultation with SEBI-registered advisors. Market conditions are volatile and subject to change. Neither the author nor the platform is responsible for losses arising from use of this information

The Upcoming IPOs in this week and coming weeks are Sambhav Steel Tubes, Ellenbarrie Indutrial Gases, Kalpataru, HDB Financials, ArisInfra Solutions, Influx Healthtech, Mayasheel Ventures, Eppeltone Engineers, Patil Automation, Samay Projects Services.

The Current active IPO are Jainik Power Cables, Monolithisch India.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.